Literature DB >> 26103439

Mathematical models of the steps involved in the systemic delivery of a chemotherapeutic to a solid tumor: From circulation to survival.

Martin B Ulmschneider1, Peter C Searson2.   

Abstract

The efficacy of an intravenously administered chemotherapeutic for treatment of a solid tumor is dependent on a sequence of steps, including circulation, extravasation by the enhanced permeability and retention effect, transport in the tumor microenvironment, the mechanism of cellular uptake and trafficking, and the mechanism of drug action. These steps are coupled since the time dependent concentration in circulation determines the concentration and distribution in the tumor microenvironment, and hence the amount taken up by individual cells within the tumor. Models have been developed for each of the steps in the delivery process although their predictive power remains limited. Advances in our understanding of the steps in the delivery process will result in refined models with improvements in predictive power and ultimately allow the development of integrated models that link systemic administration of a drug to the probability of survival. Integrated models that predict outcomes based on patient specific data could be used to select the optimum therapeutic regimens. Here we present an overview of current models for the steps in the delivery process and highlight knowledge gaps that are key to developing integrated models.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Drug delivery; Enhanced permeability and retention effect; Mathematical models; Pharmacokinetics; Survival models; Tumor growth

Mesh:

Substances:

Year:  2015        PMID: 26103439      PMCID: PMC4508231          DOI: 10.1016/j.jconrel.2015.06.026

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  57 in total

Review 1.  The structural era of endocytosis.

Authors:  M Marsh; H T McMahon
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

2.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Authors:  Laurent Claret; Pascal Girard; Paulo M Hoff; Eric Van Cutsem; Klaas P Zuideveld; Karin Jorga; Jan Fagerberg; René Bruno
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

3.  Model-based drug development in oncology: what's next?

Authors:  R Bruno; F Mercier; L Claret
Journal:  Clin Pharmacol Ther       Date:  2013-04       Impact factor: 6.875

4.  Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Authors:  Jian-Feng Lu; Erik Rasmussen; Beth Y Karlan; Ignace B Vergote; Lynn Navale; Mita Kuchimanchi; Rebeca Melara; Daniel E Stepan; David M Weinreich; Yu-Nien Sun
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-01       Impact factor: 3.333

5.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

6.  Development of a prognostic model for breast cancer survival in an open challenge environment.

Authors:  Wei-Yi Cheng; Tai-Hsien Ou Yang; Dimitris Anastassiou
Journal:  Sci Transl Med       Date:  2013-04-17       Impact factor: 17.956

7.  Does tumor growth follow a "universal law"?

Authors:  Caterina Guiot; Piero Giorgio Degiorgis; Pier Paolo Delsanto; Pietro Gabriele; Thomas S Deisboeck
Journal:  J Theor Biol       Date:  2003-11-21       Impact factor: 2.691

Review 8.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.

Authors:  Charlene M Dawidczyk; Chloe Kim; Jea Ho Park; Luisa M Russell; Kwan Hyi Lee; Martin G Pomper; Peter C Searson
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

9.  A quantitative theory of solid tumor growth, metabolic rate and vascularization.

Authors:  Alexander B Herman; Van M Savage; Geoffrey B West
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

10.  PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

Authors:  E K Hansson; G Ma; M A Amantea; J French; P A Milligan; L E Friberg; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-12-04
View more
  5 in total

1.  Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.

Authors:  Wenbo Zhan; Davis Yohanes Arifin; Timothy Ky Lee; Chi-Hwa Wang
Journal:  Pharm Res       Date:  2017-02-02       Impact factor: 4.200

Review 2.  Role of myeloid-derived suppressor cells in metastasis.

Authors:  Kathryn Cole; Kristina Pravoverov; James E Talmadge
Journal:  Cancer Metastasis Rev       Date:  2021-01-07       Impact factor: 9.264

3.  Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.

Authors:  Yongwei Gu; Juanjuan Ma; Zhiqin Fu; Youfa Xu; Baoan Gao; Jianzhong Yao; Wei Xu; Kedan Chu; Jianming Chen
Journal:  Int J Nanomedicine       Date:  2019-11-07

4.  Development of lipopolyplexes for gene delivery: A comparison of the effects of differing modes of targeting peptide display on the structure and transfection activities of lipopolyplexes.

Authors:  Robin Bofinger; May Zaw-Thin; Nicholas J Mitchell; P Stephen Patrick; Cassandra Stowe; Ana Gomez-Ramirez; Helen C Hailes; Tammy L Kalber; Alethea B Tabor
Journal:  J Pept Sci       Date:  2018-10-16       Impact factor: 1.905

5.  Impact of soft protein interactions on the excretion, extent of receptor occupancy and tumor accumulation of ultrasmall metal nanoparticles: a compartmental model simulation.

Authors:  Alioscka A Sousa
Journal:  RSC Adv       Date:  2019-08-28       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.